On 1 April 2020, the FAMHP took steps regarding a range of medicinal products in order to avoid any shortage. Following new information from scientific research, the FAMHP has added dexamethasone-based medicines and raw materials to the list of medicinal products subject to emergency measures.
Stocks of medicinal products used to treat COVID-19 patients have been closely monitored by the FAMHP since the onset of the COVID-19 crisis.
As of 1 April 2020, the FAMHP has drawn up a list of medicinal products and raw materials used in the treatment of COVID-19 for which emergency measures have been taken. These measures have since been refined and extended several times. Since mid-June 2020, these are mainly measures relating to quotas for wholesalers.
Following recent scientific information, the FAMHP has added dexamethasone to the list of products subject to the measures in order to avoid non-optimal distribution or product over-ordering, which could create the unavailability of potentially useful medicines for some COVID-19 patients and for chronic or other patients who require dexamethasone-based treatment.
Thanks to these measures and their extension, solutions and alternatives for all the medicinal products necessary for the treatment of COVID-19 patients in Belgium currently exist and will exist in the near future.
- Administrator General of the FAMHP’s decision relating to various urgent measures concerning specific medicinal products to combat the medicinal product shortage during the SARS-CoV-2 pandemic